Bhupal Ban
Director, Antibody Discovery, Protein Engineering & Development Crossbow Therapeutics
Enterprise-level scientific leader with 20+ years of experience building and directing high performing antibody discovery, engineering, and early CMC organizations across biotech and academia. Proven track record of architecting differentiated biologics platforms and advancing multispecific antibody programs from target ideation through IND enabling studies. Brings deep expertise in TCR mimetic antibodies, T cell and NK cell engagers, ADCs, and intracellular targeting strategies. Recognized for seamlessly integrating binder discovery and engineering with developability, manufacturability, and regulatory strategy to drive capital efficient pipeline progression, reduce development risk, and create durable long term portfolio value.
Seminars
- Where has computational design actually moved the needle, and how are you proving it internally to speed up drug pipelines?
- How to control for data quality and biological reality in ML-driven design loops? And what specific changes have you made to your data generation strategy to make it truly usable for training models?
- How are you deciding what to prioritize today across de novo design, optimization workflows, and engineering, given they sit at different points in the hype cycle?
